Analyst Ratings January 23, 2026

RBC Capital Adjusts Columbia Banking System's Price Target to $32 Amid Strong Q4 Performance

Analyst Highlights Solid Core Metrics Despite Acquisition Impacts and Maintains Sector Perform Rating

By Jordan Park COLB
RBC Capital Adjusts Columbia Banking System's Price Target to $32 Amid Strong Q4 Performance
COLB

RBC Capital has increased its price target on Columbia Banking System to $32 from $30 following the company's fourth-quarter results, which surpassed analyst expectations in earnings per share and revenue. While acquisition-related factors influenced the quarter, core financial indicators such as asset composition, margins, and expense management remained robust. The bank anticipates some reduction in balance sheet size and margins in the early part of the new year but expects growth afterward. Despite upbeat financials, the stock experienced a dip during after-hours trading.

Key Points

  • RBC Capital raised Columbia Banking System’s price target to $32 from $30 while maintaining a Sector Perform rating.
  • The bank’s fourth-quarter results reflected strong earnings per share and revenue, surpassing analyst estimates.
  • Columbia Banking anticipates a slightly smaller balance sheet and lower margin at the start of the year, with growth expected after Q1 and controlled expenses throughout.
Following Columbia Banking System's recent fourth-quarter financial disclosure, RBC Capital has revised its price target upwards to $32 from the previous $30 while upholding a Sector Perform recommendation on the stock. According to Jon G. Arfstrom, RBC Capital’s analyst, the quarter was affected by the acquisition of Pacific Premier, finalized at the end of August. Despite this, the bank showcased resilient operational trends, including a positive shift in asset mix, sustained margin strength, and tight control over expenses. Management has projected that the bank's balance sheet will be somewhat smaller and that margin levels may be lower at the start of the upcoming year. Nevertheless, expectations include growth in both balance sheet size and margins after the first quarter, with stable operating expenses and moderated performance following a planned conversion process in the third quarter. RBC Capital’s outlook for Columbia Banking System remains constructive, with the recent price target adjustment reflecting confidence in the bank’s future trajectory while sustaining a neutral stance through the Sector Perform rating. In addition to these updates, the company's fourth-quarter earnings results for 2025 notably exceeded market anticipations. The operating earnings per share reached $0.82, surpassing forecasts of $0.72. Revenue also outpaced predictions, totaling $717 million against an expected $695.26 million. These figures reaffirm Columbia Banking System's capacity to deliver robust financial outcomes. Despite this strong performance, the stock saw a decrease in after-hours trading, drawing attention from investors and market analysts regarding the company's near-term prospects. The release underscores Columbia Banking System’s sound financial foundation and operational efficiency amid ongoing integration activities. It also highlights the importance of monitoring balance sheet dynamics and margin fluctuations in the forthcoming quarters as the bank navigates its post-acquisition phase.

Risks

  • The recent acquisition of Pacific Premier introduced integration-related impacts affecting financial metrics and may contribute to near-term uncertainties in balance sheet and margin performance.
  • Initial expectations for a reduced balance sheet and compressed margin in early 2025 could put pressure on quarterly financial results before growth resumes.
  • Declining after-hours stock performance despite positive earnings may indicate market apprehension about post-acquisition execution and future profitability.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026